All In Biotech

Drug Trial Radar · NCT05725018

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 2, 2023

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Abeona Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Feb 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.

Conditions

  • Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • RDEB

Interventions

  • EB-101 Surgical application of RDEB woundsBiological

    EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7 Other Names: • LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs)Time frame: 6 months
  2. Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.)Time frame: 6 months
  3. Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )Time frame: 6 months
  4. Safety Endpoint (Incidence of squamous cell carcinoma)Time frame: 6 months
  5. Safety Endpoint RCR statusTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Redwood City, California

  • University of Massachusetts Medical School

    Worcester, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.